Ref. No.: JPL/CS/1636/2020

Date: 24th July, 2020.

To
BSE Ltd.,
P J Towers,
Dalal Street,
Mumbai - 400 001.

Ref.: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

In continuation to our letter under captioned regulation, dated 21st July, 2020, regarding launch of FAVIPIRAVIR-200mg tablet, kindly note that the Company will very soon launch it under the trade name FAVIVENT.

The FAVIVENT is a prescription only medicine for the treatment of mild to moderate Covid-19.

FAVIVENT will be priced at Rs. 39/- per tablet.

Kindly find attached media release and presentation, in this regard, to be released today.

For Jenburkt Pharmaceuticals Limited

ASHISH R SHAH

Ashish R Shah
Company Secretary and Compliance Officer
PRESS RELEASE
24.07.2020 | Mumbai, India
Jenburkt Pharmaceuticals Ltd. second in India to launch Favipiravir (Favivent™) to fight COVID-19

Mumbai, India; 24th July 2020: India has recently crossed the 1.28 million mark of COVID-19 cases and has turned into a global hotspot of coronavirus. In an important development for COVID-19 patients in India, Jenburkt Pharmaceuticals Ltd., a public listed company headquartered in Mumbai with a legacy of over 30 years in high-quality pharmaceutical solutions, and having international presence, announced the launch of antiviral drug Favipiravir (brand name Favivent™) for the treatment of mild to moderate COVID-19 symptoms at a price of Rs. 39 per tablet.

This is not the first foray into timely, rapid innovation from the Jenburkt stable. This innovation-driven organisation was the first in the world to introduce Nervijen, Metmin-A, Powergesic, Infartin and a few more, across multiple therapeutic areas. The company’s R&D unit, approved by the Ministry of Science & Technology, Government of India, is their gateway to health through innovation.
Jenburkt is the second in India to introduce Favipiravir (brand name Favivent™) for the treatment of COVID-19. Favivent™ is manufactured at a pharmaceutical plant which is compliant with US-FDA (U. S. Food and Drug Administration) and EDQM (The European Directorate for the Quality of Medicines & HealthCare) standards located in the state of Telangana, with the highest safety and manufacturing protocols in place. According to Jenburkt, the medication will be available in the form of 1 strip of 10 tablets.

Earlier this year, the Drug Controller General of India approved the use of favipiravir — an antiviral drug developed in Japan and commonly used for treating influenza — for the treatment of mild to moderate cases of COVID-19 in India. Favipiravir is a broad spectrum anti-viral agent and selectively inhibits RNA polymerase of influenza virus and prevents viral replication. Favipiravir has a proven efficacy against a wide range of influenza viruses including strains resistant to existing anti-influenza drugs.

Commenting on the significance of this development, Mr. Ashish U. Bhuta, Chairman and Managing Director of Jenburkt Pharmaceuticals Ltd. said,

“Our endeavor has always been to serve our patients - through them, we serve God, humanity and our nation. Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, if we as a pharmaceutical company cannot make a significant positive difference to the society, our company’s very existence is inconsequential. It is only Conscious Capitalism and Innovation which can sustain growth of any organisation in the long run.”
Countries across the world have a generally positive outlook on Favipiravir. Favipiravir has been approved for use against COVID-19 not just in India, but also in Japan, Russia and parts of the Middle East.

Favivent™ (Favipiravir 200 mg) can benefit patients showing mild to moderate symptoms of COVID-19. It will be available as a prescription-only drug and is to be administered in the prescribed dosage under a certified practicing doctor’s supervision only with the informed consent of the patient.

Mr. Bhuta added, "With the rising number of cases, our country’s medical infrastructure and front-line warriors are under tremendous pressure at the moment. We hope the easy accessibility and affordable price point of an effective treatment such as Favivent™ will offer our citizens a timely, much-needed therapeutic solution."

"At Jenburkt, we think of philanthropy as a unique instrument of social innovation that leads to more resilient, healthy citizens, and our organisation has a long legacy of giving back to society. We plan to work closely with local and government organisations, along with the medical community, to ensure that the product is made available to COVID-19 patients at the earliest", shared Mr. Ashish U. Bhuta in terms of way forward with the product.
Founded in 1985, Jenburkt Pharmaceuticals Ltd is a deeply-trusted public-listed pharmaceutical organisation headquartered in Mumbai, India with a presence spanning 13 countries. Our purpose at Jenburkt Pharmaceuticals Ltd is to serve those in need of quality healthcare by bringing revolutionary, life-changing therapeutic solutions that are accessible to all.

Way back in the twentieth century, a visionary in the field of healthcare and philanthropic work – Shri Nandlal Mulji Bhuta laid the foundation for several groups of companies. Continuing the legacy of Shri Nandlal Mulji Bhuta, his sons Mr. Uttam N. Bhuta and Mr. Hemendra N. Bhuta founded Jenburkt Pharmaceuticals Ltd. in year 1985.

In an ever-changing health landscape, our rapt attention to market trends, innovation, our keen focus on quality above all else, and our team’s restless perseverance to deliver ground-breaking new healthcare solutions set us apart. Today, with over 850+ committed team members across functions pan-India, we have 11 million+ prescriptions generated annually across the globe. Our organisation caters to large government, semi-government institutions, missionary hospitals, public sector enterprises etc.

Further, the impact of our philanthropic foundations and programs is significant and far-reaching, impacting thousands of people across ages across the country annually. We have established the Maniben Mulji Bhuta Charitable Dispensary and Jamnaben Bhuta General Hospital in Sihor, Gujarat, Nandlal Bhuta School and Nandlal Bhuta College of Commerce & Management & Jamnaben Bhuta College of Arts in Sihor, Gujarat, along with a mammography centre, electro-magnetic therapy centre and electric cremation facility among other charitable initiatives.
WHO WE ARE

• Headquartered in *Mumbai, India.*

• A company listed on Bombay Stock Exchange

• A *deeply-trusted Professionally run pharmaceutical organisation* with a presence spanning 13 countries and empowering over 850 team members.

• With every step, we continue to pursue our Founders’ noble vision and guiding principle of *bringing health and happiness to all by delivering excellence in life sciences.*

• Our keen focus on *quality* above all else, and our team’s restless perseverance to deliver ground-breaking new healthcare solutions set us apart.
4,00,000 + Pharmacies reached across the Globe

11 Million+ Prescriptions Generated Annually

1,05,000+ Doctor interactions Annually

850+ Team Members

PRIVATE AND CONFIDENTIAL
Revolutionary New Products Launched By Us
For the First Time in the World
Across Multiple Therapeutic Areas

Nervijen  Nervijen-P  Metmin-A  Powergesic  CartiSafe-Forte  INFARTIN

Revolutionary New Products Launched By Us
Second in India
Across Multiple Therapeutic Areas

Oxicojen  Eberjen  Zix-PG 200/75  Nervijen-CT  Powergesic 2x Gel/Spray
Our Mission

We wish to serve our patients - through them serve God, humanity and nation. Nothing gratifies us more than bringing a smile to our patient's faces.

Our Vision

We seek to deliver excellence in life sciences by weaving together in-depth research, efficient use of resources and our unparalleled network to build premium-quality pharmaceutical formulations to bring positive change to families around the world.
What Sets Us Apart

R & D
Our R & D unit, approved by the Ministry of Science & Technology, Govt. of India, is the gateway to health through innovation.

Quality Assurance
Safe & consistent standard of products backed with modern Quality Control Laboratory having sophisticated equipment

Manufacturing
WHO-GMP approved state-of-the-art plant at Sihor, Gujarat with extensive pharmaceutical manufacturing facilities.

HR
Our progressive people-centric HR policies and professional development initiatives give us a competitive edge.

Marketing - India & Global
With a robust sales force, we promote our brands across 105,000+ doctors in India, along with exports to 13 countries globally.

Technology
Adopting SAP (S4 HANA), LIMS and SFA enhances company’s efficiency, reliability and accuracy.
Our Commitment to Quality

• Major thrust on Quality Assurance, by setting up reliable processes and strict adherence to guidelines across all departments to ensure best quality products

• Good Laboratory Practices (GLP) standards followed

• Use of latest technology and system driven processes such as Laboratory Information Management System (LIMS) and SAP (the latest version of SAP i.e. S4 HANA)

• State-of-the-art Quality control laboratory equipped with qualified team of professionals and world class testing facilities like HPLC, UPLC, UV Spectrometer, FTIR, Automated Dissolution Testing System
Our Philanthropic Initiatives
A Long Legacy of Giving Back by the Bhuta Family

Nandlal Bhuta School
Jamnaben Bhuta General Hospital
Nandlal Bhuta College of Commerce & Management & Jamnaben Bhuta College of Arts
At Jenburkt, we think of philanthropy as a unique instrument of social innovation that leads to more resilient, healthy citizens.

The impact of our foundations and programs is significant and far-reaching, impacting thousands of people across ages across the country annually.

We are committed to supporting charitable causes and building sustainable organizations in the communities in which we operate.
Awards of Repute

Excellence in Cost Management Award 2010
Conferred By ICWAI (Institute Of Cost & Works Accountants Of India)

Excellence in Cost Management Award 2011
Conferred By ICWAI (Institute Of Cost & Works Accountants Of India)

Financial Express Global CFO Award
Conferred by Deepak Parekh (A Financial Luminary)
PROUDLY INTRODUCING

**Favipiravir 200 mg Tablets**

Vents out COVID-19.. Effectively

For adults with mild-to-moderate COVID-19

Price **Rs.39** per tablet

Excellent Quality with Affordable Price

*DCGI Approved oral antiviral in Mild to Moderate COVID-19

Manufactured in a plant compliant with US-FDA and EDQM standards.

* Favipiravir 200 mg is approved by DCGI (Drugs Controller General of India) under accelerated approval process considering the emergency situation and unmet medical need in light of Covid-19 outbreak, for restricted emergency use in the country.

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.

Prescription-only Medicine: to be administered in prescribed dosage under a certified medical practitioner's supervision.